Status:
COMPLETED
Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia
Lead Sponsor:
Assiut University
Conditions:
Autoimmune Hemolytic Anemia
Eligibility:
All Genders
18+ years
Brief Summary
Autoimmune hemolytic anemia is characterized by shortened red blood cell survival and a positive Coombs test. The responsible autoantibodies may be either warm reactive or cold reactive. The rate of h...
Detailed Description
Hemolysis is the premature destruction of erythrocytes. A hemolytic anemia will develop if bone marrow activity cannot compensate for the erythrocyte loss. The severity of the anemia depends on whethe...
Eligibility Criteria
Inclusion
- patients diagnosed warm auto Immune hemolytic anemia primary or secondary(CLL, Lymphoma, rheumatoid arthritis
- , SLE,Drug-induced )
Exclusion
- All types of congenital hemolytic anemia
- Microangiopathic hemolytic anemia ( Thrombotic thrombocytopenic purpura (TTP) , Hemolytic-uremic syndrome (HUS) , Disseminated intravascular coagulation (DIC) )
- Alloimmune hemolytic anemia
- pregnancy
Key Trial Info
Start Date :
October 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 24 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03269292
Start Date
October 1 2017
End Date
January 24 2021
Last Update
April 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Hospital
Asyut, Egypt